Prelude Therapeutics Inc (OQ:PRLD)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 175 Innovation Boulevard
WILMINGTON DE 19805
Tel: N/A
Website: https://preludetx.com
IR: See website
<
Key People
Jane Huang
President, Chief Medical Officer
Krishna Vaddi
Chief Executive Officer, Founder, Director
Bryant D. Lim
Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary
Andrew P. Combs
Executive Vice President, Head of Chemistry
Peggy A. Scherle
Chief Scientific Officer
 
Business Overview
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Financial Overview
For the fiscal year ended 31 December 2023, Prelude Therapeutics Inc revenues was not reported. Net loss increased 6% to $121.8M. Higher net loss reflects Research and development increase of 12% to $90.8M (expense), Stock-based Compensation in R&D increase of 9% to $12.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.44 to -$2.02.
Employees: 128 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$131.11M as of Dec 31, 2023
Net annual income (TTM): -$121.83M as of Dec 31, 2023
Free cash flow (TTM): -$110.58M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 54,920,594 as of Feb 9, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.